Equip Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 34)
Equip Health logo

Equip Health

EmergingMental Health Tech

Eating Disorder Treatment

Virtual eating disorder treatment using family-based therapy, San Diego CA, raised $58M+. First at-home model for anorexia and bulimia treatment in the US.

AI VisibilityBeta
Overall Score
D34
Category Rank
#590 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
30
Perplexity
30
Gemini
32

About

Equip Health is a San Diego, California-based virtual care company founded in 2019 that specializes in treating eating disorders including anorexia, bulimia, binge eating disorder, and avoidant restrictive food intake disorder (ARFID). The company has raised over $58 million and has pioneered a virtual delivery model for family-based treatment (FBT), the gold-standard evidence-based therapy for adolescent eating disorders, making intensive evidence-based care accessible outside of residential treatment programs.\n\nEquip's care model assembles a five-person care team for each patient: a therapist, a dietitian, a physician, a family mentor, and a peer mentor — all coordinating through the platform. This team-based virtual approach mirrors the multidisciplinary structure of leading eating disorder treatment centers while eliminating the geographic and financial barriers that prevent most patients from accessing residential care. Sessions are conducted by video with the patient and their family, with meal support and between-session coaching embedded in the program.\n\nThe company distributes its services through insurance coverage, accepting major commercial plans and working to expand Medicaid coverage. Eating disorders carry the highest mortality rate of any psychiatric illness, yet treatment access is severely limited in the United States. Equip's virtual model has treated patients across all 50 states, demonstrating the feasibility of delivering intensive eating disorder care at home and positioning the company as a national provider in a historically fragmented specialty.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

34
Overall Score
93
#590
Category Rank
#1
74
AI Consensus
80
stable
Trend
stable
30
ChatGPT
94
30
Perplexity
89
32
Gemini
94
40
Claude
92
30
Grok
98

Key Details

Category
Eating Disorder Treatment
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Equip Health
Eating Disorder Treatment

Integrations

Only Pfizer
Pfizer is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.